KURA ONCOLOGY INC
KURANASDAQTrading Snapshot
- Day Range
- $10.50 – $10.96
- 52-Week Range
- $7.36 – $13.90
- Volume (shares)
- 1,590,228
- Avg Volume (shares)
- —
- Shares Outstanding
- 89.0M
- Next Earnings
- 2027-03-03
Fundamentals Snapshot
- Annual Revenue
- $67M
- Last Q Revenue
- $21M
- P/E Ratio
- -3.2
- P/S Ratio
- 12.3x
- EPS (TTM)
- $-3.34
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +1.0%
KURA ONCOLOGY INC
KURA
StockOtter · stockotter.spaceAbout KURA ONCOLOGY INC
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Ratings
ⓘLatest News & Updates
Will Kura Oncology (KURA) Report Negative Q3 Earnings? What You Should Know
Kura Oncology (KURA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Kura Oncology Launches $50M-Backed Diabetes Venture for Oral Menin Inhibitor
Kura Oncology NASDAQ: KURA and its newly formed affiliate Caspian Therapeutics outlined plans to develop KO-7246, an oral menin inhibitor, for diabetes, citing preclinical data that the companies said showed beta-cell ex
Kura Oncology, Inc. (KURA) Discusses KO-7246 Data and Development Strategy for Menin Inhibitors in Diabetes Transcript
Kura Oncology, Inc. (KURA) Discusses KO-7246 Data and Development Strategy for Menin Inhibitors in Diabetes Transcript
Caspian Therapeutics and Kura Oncology Outline KO-7246 Development Strategy in Diabetes
– EASD findings support clinical evaluation of a next-generation oral menin inhibitor designed to restore insulin-producing capacity – – IND-enabling development underway to support Phase 1 clinical proof-of-concept stud
Caspian Therapeutics and Kura Oncology to Host Investor Webcast Highlighting Caspian's Launch and KO-7246 Preclinical Data in Diabetes
– Webcast scheduled for October 13, 2026, at 4:30 p.m. ET / 1:30 p.m. PT – – Webcast scheduled for October 13, 2026, at 4:30 p.m. ET / 1:30 p.m. PT –
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Oct. 02, 2026 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a biopharmaceutical company focused on precision medicines for the treatment of cancer, today announced that on October 1,